WO2000027819A3 - Anthranilsäureamide und deren verwendung als arzneimittel - Google Patents

Anthranilsäureamide und deren verwendung als arzneimittel Download PDF

Info

Publication number
WO2000027819A3
WO2000027819A3 PCT/EP1999/008478 EP9908478W WO0027819A3 WO 2000027819 A3 WO2000027819 A3 WO 2000027819A3 EP 9908478 W EP9908478 W EP 9908478W WO 0027819 A3 WO0027819 A3 WO 0027819A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid amides
medicaments
antrhranilic
anthranilic acid
triggered
Prior art date
Application number
PCT/EP1999/008478
Other languages
English (en)
French (fr)
Other versions
WO2000027819A2 (de
Inventor
Andreas Huth
Dieter Seidelmann
Karl-Heinz Thierauch
Guido Bold
Paul William Manley
Pascal Furet
Jeanette Marjorie Wood
Juergen Mestan
Jose Brueggen
Stefano Ferrari
Martin Krueger
Eckhard Ottow
Andreas Menrad
Michael Schirner
Original Assignee
Schering Ag
Novartis Ag
Andreas Huth
Dieter Seidelmann
Thierauch Karl Heinz
Guido Bold
Paul William Manley
Pascal Furet
Jeanette Marjorie Wood
Juergen Mestan
Jose Brueggen
Stefano Ferrari
Martin Krueger
Eckhard Ottow
Andreas Menrad
Michael Schirner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824579.8A external-priority patent/GB9824579D0/en
Priority claimed from DE1999110396 external-priority patent/DE19910396C2/de
Priority to UA2001063917A priority Critical patent/UA71587C2/uk
Priority to BR9915553-2A priority patent/BR9915553A/pt
Priority to JP2000580999A priority patent/JP2002529452A/ja
Priority to HU0104425A priority patent/HUP0104425A3/hu
Priority to EA200100524A priority patent/EA004701B1/ru
Priority to EEP200100258A priority patent/EE200100258A/xx
Priority to EP99953967A priority patent/EP1129074A2/de
Priority to AU10454/00A priority patent/AU771180B2/en
Application filed by Schering Ag, Novartis Ag, Andreas Huth, Dieter Seidelmann, Thierauch Karl Heinz, Guido Bold, Paul William Manley, Pascal Furet, Jeanette Marjorie Wood, Juergen Mestan, Jose Brueggen, Stefano Ferrari, Martin Krueger, Eckhard Ottow, Andreas Menrad, Michael Schirner filed Critical Schering Ag
Priority to CA002350208A priority patent/CA2350208A1/en
Priority to PL99348349A priority patent/PL348349A1/xx
Priority to US09/831,506 priority patent/US7122547B1/en
Priority to SK607-2001A priority patent/SK6072001A3/sk
Priority to NZ511413A priority patent/NZ511413A/en
Publication of WO2000027819A2 publication Critical patent/WO2000027819A2/de
Publication of WO2000027819A3 publication Critical patent/WO2000027819A3/de
Priority to NO20012245A priority patent/NO320647B1/no
Priority to HK02103628A priority patent/HK1041882A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Es werden Anthranilsäureamide und deren Verwendung als Arzneimittel zur Behandlung von Erkrankungen, die durch persistente Angiogenese ausgelöst werden, sowie deren Zwischenprodukte zur Herstellung der Anthranilsäureamide beschrieben.
PCT/EP1999/008478 1998-11-10 1999-11-09 Anthranilsäureamide und deren verwendung als arzneimittel WO2000027819A2 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
UA2001063917A UA71587C2 (uk) 1998-11-10 1999-09-11 Аміди антранілової кислоти та їхнє застосування як лікарських засобів
SK607-2001A SK6072001A3 (en) 1998-11-10 1999-11-09 Anthranilic acid amides and the use thereof as medicaments
NZ511413A NZ511413A (en) 1998-11-10 1999-11-09 Antrhranilic acid amides and the use thereof as medicaments
PL99348349A PL348349A1 (en) 1998-11-10 1999-11-09 Antrhranilic acid amides and the use thereof as medicaments
HU0104425A HUP0104425A3 (en) 1998-11-10 1999-11-09 Anthranilic acid amides and the use thereof for the treatment of angiogenesis
EA200100524A EA004701B1 (ru) 1998-11-10 1999-11-09 Амиды антраниловой кислоты и их применение в качестве лекарственных средств
EEP200100258A EE200100258A (et) 1998-11-10 1999-11-09 Antraniilhappe amiidid ja nende kasutamine ravimitena
EP99953967A EP1129074A2 (de) 1998-11-10 1999-11-09 Anthranilsäureamide und deren verwendung als arzneimittel
AU10454/00A AU771180B2 (en) 1998-11-10 1999-11-09 Antrhranilic acid amides and the use thereof as medicaments
BR9915553-2A BR9915553A (pt) 1998-11-10 1999-11-09 Amidas de ácido antranìlico e seu emprego como medicamento
CA002350208A CA2350208A1 (en) 1998-11-10 1999-11-09 Antrhranilic acid amides and the use thereof as medicaments
JP2000580999A JP2002529452A (ja) 1998-11-10 1999-11-09 アントラニル酸アミド及び医薬剤としてのその使用
US09/831,506 US7122547B1 (en) 1998-11-10 1999-11-09 Anthranilic acid amides and the use thereof as medicaments
NO20012245A NO320647B1 (no) 1998-11-10 2001-05-07 Anthranilsyreamider og anvendelse derav for fremstilling av medikamenter
HK02103628A HK1041882A1 (en) 1998-11-10 2002-05-14 Anthranilic acid amides and their use in manufacturing pharmaceutical agents.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9824579.8A GB9824579D0 (en) 1998-11-10 1998-11-10 Organic compounds
GB9824579.8 1998-11-10
DE19910396.8 1999-03-03
DE1999110396 DE19910396C2 (de) 1999-03-03 1999-03-03 Anthranilsäureamide und deren Verwendung als Arzneimittel

Publications (2)

Publication Number Publication Date
WO2000027819A2 WO2000027819A2 (de) 2000-05-18
WO2000027819A3 true WO2000027819A3 (de) 2000-08-17

Family

ID=26052266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/008478 WO2000027819A2 (de) 1998-11-10 1999-11-09 Anthranilsäureamide und deren verwendung als arzneimittel

Country Status (23)

Country Link
US (1) US7122547B1 (de)
EP (1) EP1129074A2 (de)
JP (1) JP2002529452A (de)
KR (2) KR100855396B1 (de)
CN (1) CN1151133C (de)
AU (1) AU771180B2 (de)
BG (1) BG65371B1 (de)
BR (1) BR9915553A (de)
CA (1) CA2350208A1 (de)
CZ (1) CZ20011631A3 (de)
EA (1) EA004701B1 (de)
EE (1) EE200100258A (de)
HK (1) HK1041882A1 (de)
HR (1) HRP20010402A2 (de)
HU (1) HUP0104425A3 (de)
NO (1) NO320647B1 (de)
NZ (1) NZ511413A (de)
PL (1) PL348349A1 (de)
SK (1) SK6072001A3 (de)
TR (1) TR200101307T2 (de)
UA (1) UA71587C2 (de)
WO (1) WO2000027819A2 (de)
YU (1) YU31801A (de)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE272633T1 (de) * 1998-12-23 2004-08-15 Lilly Co Eli Aromatische amiden
DE10023485A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
CN1234358C (zh) * 2000-06-21 2006-01-04 弗·哈夫曼-拉罗切有限公司 苯并噻唑衍生物
AU3950802A (en) 2000-12-07 2002-06-18 Cv Therapeutics Inc Abca-1 elevating compounds
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
PT3351246T (pt) 2001-02-19 2019-06-07 Novartis Pharma Ag Derivado de rapamicina para o tratamento de um tumor sólido associado a angiogenese desregulada
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
US7429592B2 (en) * 2001-05-08 2008-09-30 Schering Aktienegesellschaft Cyanoanthranilamide derivatives and the use thereof as medicaments
DE10123587B4 (de) * 2001-05-08 2005-04-07 Schering Ag Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel
CN1518546A (zh) * 2001-05-08 2004-08-04 ���ֹɷݹ�˾ 作为vegrf-2和vegfr-3抑制剂的选择性邻氨基苯甲酰胺吡啶酰胺
US7459470B2 (en) 2001-05-08 2008-12-02 Schering Ag N-oxide anthranylamide derivatives and their use as medicaments
DE10123573B4 (de) * 2001-05-08 2005-06-02 Schering Ag N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel
PL392652A1 (pl) 2001-05-16 2010-12-06 Novartis Ag Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację
EP1403255A4 (de) * 2001-06-12 2005-04-06 Sumitomo Pharma Rho-kinase-inhibitoren
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
ATE511840T1 (de) 2001-10-09 2011-06-15 Amgen Inc Imidazolderivate als entzündungshemmende mittel
GB0126902D0 (en) * 2001-11-08 2002-01-02 Novartis Ag Organic compounds
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EP1944026B1 (de) 2002-05-16 2013-06-26 Novartis AG Verwendung von EDG-Rezeptorbindemitteln bei Krebs
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7094789B2 (en) 2002-07-22 2006-08-22 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivatives
DE10235690A1 (de) * 2002-07-31 2004-02-19 Schering Ag VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide
US7615565B2 (en) * 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
EP1388341A1 (de) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Substituierte Acylamino heteroaromatische Verbindungen und ihre Verwendung als Arztneimittel
DE60329030D1 (de) 2002-12-04 2009-10-08 Ore Pharmaceuticals Inc Melanocortin-rezeptormodulatoren
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
EP1603883B1 (de) * 2003-02-03 2012-03-28 Janssen Pharmaceutica NV Chinolin-amid-derivate als modulatoren von vanilloid-vr1-rezeptoren
US7531558B2 (en) 2003-02-14 2009-05-12 Glaxo Group Limited Carboxamide derivatives
WO2004078723A1 (ja) 2003-03-07 2004-09-16 Santen Pharmaceutical Co. Ltd. ４－ピリジルアルキルチオ基を置換基として有する新規化合物
CA2524048C (en) 2003-05-19 2013-06-25 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
EP1628661A2 (de) * 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Vr1-rezeptor-modulatoren
US7202260B2 (en) 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
DE10327719A1 (de) * 2003-06-13 2005-01-20 Schering Ag VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
EP1653951B1 (de) * 2003-07-11 2011-12-28 Merck Patent GmbH Benzimidazol-derivative als raf-kinase-hemmer
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
PL1717229T3 (pl) 2004-02-17 2011-11-30 Santen Pharmaceutical Co Ltd Nowy cykliczny związek mający grupę 4-pirydyloalkilotiolową z wprowadzoną do niej (nie)podstawioną grupą aminową
EP1568368A1 (de) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmazeutische Kombination enthaltend einen CDK Inhibitoren und einen VEGF Rezeptor Inhibitoren
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
US7427390B2 (en) * 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
DE102004011720B4 (de) * 2004-03-10 2008-04-03 Bayer Schering Pharma Aktiengesellschaft Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie
EA011279B1 (ru) 2004-05-24 2009-02-27 Ф. Хоффманн-Ля Рош Аг (4-метокси-7-морфолин-4-илбензотиазол-2-ил)-амид 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты
DE102004039876A1 (de) * 2004-06-23 2006-01-26 Lanxess Deutschland Gmbh Herstellung von fluorierten 1,3-Benzodioxanen
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
KR101331786B1 (ko) * 2004-09-22 2013-11-21 얀센 파마슈티카 엔.브이. Ｍｄｍ2 및 ｐ53간의 상호작용 저해제
EP1655297A1 (de) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamidpyridinharnstoffe als Kinaseinhibitoren des Rezeptors des vaskulären endothelialen Wachstumsfaktors (VEGF)
EP1655295A1 (de) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamid-Pyridinharnstoffe als VEGF Rezeptor Kinase Inhibitoren
EP1657241A1 (de) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Neue Antranilamidpyrdinharnstoffe mit hemmender Wirkung auf VEGF-Rezeptor Kinase
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
JP4633123B2 (ja) 2004-11-05 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー イソニコチン酸誘導体の製造方法
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
DE602006016564D1 (de) 2005-03-03 2010-10-14 Santen Pharmaceutical Co Ltd Neue cyclische verbindung mit chinolylalkylthiogruppe
KR100968989B1 (ko) 2005-03-23 2010-07-09 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘 유도체
ES2548729T3 (es) 2005-03-31 2015-10-20 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que tiene grupo pirimidinilalquiltio
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN101273040B (zh) 2005-09-27 2011-11-09 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的*二唑基吡唑并嘧啶类化合物
AR058065A1 (es) 2005-09-27 2008-01-23 Novartis Ag Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas.
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
CA2629245C (en) 2005-11-21 2016-07-12 Novartis Ag Neuroendocrine tumor treatment
US8106190B2 (en) * 2005-11-30 2012-01-31 Astellas Pharma Inc. 2-aminobenzamide derivatives
EP2001868B1 (de) 2006-03-22 2013-07-17 Janssen Pharmaceutica N.V. Inhibitoren der wechselwirkung zwischen mdm2 und p53
US8088795B2 (en) 2006-03-22 2012-01-03 Janssen Pharmaceutica N.V. Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53
CN101415409B (zh) 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
CN101443002B (zh) 2006-05-09 2012-03-21 诺瓦提斯公司 包含铁螯合剂和抗肿瘤药的组合及其用途
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
WO2008077809A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Process for the manufacture of 7-oxa-bicyclo derivatives
US8063034B2 (en) 2007-01-29 2011-11-22 Santen Pharmaceutical Co., Ltd. Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
CN101626758A (zh) 2007-02-15 2010-01-13 诺瓦提斯公司 用于治疗癌症的lbh589和其他治疗剂的组合
EP1975166A1 (de) * 2007-03-30 2008-10-01 Bayer Schering Pharma AG Synthese von Anthranilamiden
TW200922557A (en) * 2007-08-06 2009-06-01 Janssen Pharmaceutica Nv Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53
EP2260020B1 (de) 2008-03-26 2014-07-23 Novartis AG Auf hydroxamat basierende hemmer von deacetylasen b
CA2734551A1 (en) 2008-08-27 2010-03-04 Leo Pharma A/S Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
EP2344161B1 (de) 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Kombinationen eines liposomalen wasserlöslichen camptothecins mit cetuximab oder bevacizumab
MX2011006622A (es) 2008-12-18 2011-07-12 Novartis Ag Sales novedosas.
DK2676953T3 (en) 2008-12-18 2017-07-03 Novartis Ag Hemifumarate salt of 1- [4- [1- (4-cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl] -acetidine-3-carboxylic acid for use in the treatment of lymphocyte-mediated diseases
JP2012512884A (ja) 2008-12-18 2012-06-07 ノバルティス アーゲー １−（４−｛１−［（ｅ）−４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ］−エチル｝−２−エチル−ベンジル）−アゼチジン−３−カルボン酸の新規の多形相
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
BRPI1008855B8 (pt) 2009-02-04 2021-05-25 Janssen Pharmaceutica Nv derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende
DK2445903T3 (da) 2009-06-26 2014-06-23 Novartis Ag 1,3-Disubstituerede imidazolidin-2-on-derivater som CYP17-inhibitorer
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
IN2012DN01693A (de) 2009-08-26 2015-06-05 Novartis Ag
CN102596963A (zh) 2009-09-10 2012-07-18 诺瓦提斯公司 二环杂芳基的醚衍生物
BR112012010519A2 (pt) 2009-11-04 2017-12-05 Novartis Ag derivados de sulfonamida heterocíclicos
JP2013512215A (ja) 2009-11-25 2013-04-11 ノバルティス アーゲー 二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
EA201200823A1 (ru) 2009-12-08 2013-02-28 Новартис Аг Гетероциклические производные сульфонамидов
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
WO2011157787A1 (en) 2010-06-17 2011-12-22 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
US20130085161A1 (en) 2010-06-17 2013-04-04 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
RU2618475C2 (ru) 2010-09-10 2017-05-03 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2683722A1 (de) 2011-03-08 2014-01-15 Novartis AG Bicyclische fluorphenyl-heteroarylverbindungen
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
ES2656218T3 (es) 2011-04-28 2018-02-26 Novartis Ag Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa
CA2838029A1 (en) 2011-06-09 2012-12-13 Novartis Ag Heterocyclic sulfonamide derivatives
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EP2755976B1 (de) 2011-09-15 2018-07-18 Novartis AG 6-substituierte 3-(chinolin-6-ylthio)-[1,2,4-]triazolo-[4,3-a-]pyradine als tyrosinkinase
JP5992054B2 (ja) 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
CA2859876A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
BR112014015308A2 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com contrapartes de ligação
CA2859869A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
CN102603729A (zh) * 2012-01-12 2012-07-25 贵州大学 N-(2-(取代苯并噻唑-2-氨基甲酰基)-取代苯基)吡啶甲酰胺类衍生物
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
US9725427B2 (en) 2012-03-16 2017-08-08 Biohaven Pharmaceutical Holding Company Limited Prodrugs of riluzole and their method of use
CA2868202C (en) 2012-04-03 2021-08-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
SG11201406468YA (en) 2012-04-13 2015-01-29 Epizyme Inc Salt form of a human hi stone methyltransf erase ezh2 inhibitor
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
PE20150887A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
EP2948453B1 (de) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinonverbindungen als inhibitoren der p53/mdm2-interaktion
CA2906542A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CN103130696B (zh) * 2013-03-21 2014-06-11 山东大学 邻氨基苯甲酰胺类化合物及其制备方法与应用
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
CN103405434A (zh) * 2013-08-22 2013-11-27 中国药科大学 Vegfr-2抑制剂及其用途
AU2014337300B2 (en) 2013-10-16 2019-01-03 Eisai R&D Management Co., Ltd. Hydrochloride salt form for EZH2 inhibition
CN104163794A (zh) * 2013-10-17 2014-11-26 中国药科大学 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
EP3697425A1 (de) 2017-10-18 2020-08-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Verfahren und verbindungen zur verbesserten immunzelltherapie
JP7021356B2 (ja) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
WO2022222890A1 (en) * 2021-04-19 2022-10-27 Shanghai Yao Yuan Biotechnology Co., Ltd. Benzothiazole and quinoline derivatives for use in treating kawasaki disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409668A (en) * 1964-11-07 1968-11-05 Palazzo Giuseppe Substituted anthranilamides and process for the preparation thereof
JPS50157383A (de) * 1974-05-24 1975-12-19
DE2652144A1 (de) * 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
DE3406416A1 (de) * 1983-02-28 1984-08-30 American Cyanamid Co., Wayne, N.J. N-((omega)-(1h-imidazol-l-yl)-alkyl)-arylamide
EP0564356A1 (de) * 1992-04-01 1993-10-06 Fournier Industrie Et Sante 4-Phenylaminomethylimidazolderivate, Verfahren zu ihrer Herstellung, Angiotensin-II-Rezeptor Antagonisten und ihre therapeutische Verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226394A (en) * 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
US4568687A (en) 1983-02-28 1986-02-04 American Cyanamid Company N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions
AU694465B2 (en) * 1993-12-27 1998-07-23 Eisai Co. Ltd. Anthranilic acid derivative
PT888353E (pt) * 1996-03-15 2003-11-28 Novartis Ag Novas n-7-heterociclil-pirrolo¬2,3-d|pirimidinas e sua aplicacao

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409668A (en) * 1964-11-07 1968-11-05 Palazzo Giuseppe Substituted anthranilamides and process for the preparation thereof
JPS50157383A (de) * 1974-05-24 1975-12-19
DE2652144A1 (de) * 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
DE3406416A1 (de) * 1983-02-28 1984-08-30 American Cyanamid Co., Wayne, N.J. N-((omega)-(1h-imidazol-l-yl)-alkyl)-arylamide
EP0564356A1 (de) * 1992-04-01 1993-10-06 Fournier Industrie Et Sante 4-Phenylaminomethylimidazolderivate, Verfahren zu ihrer Herstellung, Angiotensin-II-Rezeptor Antagonisten und ihre therapeutische Verwendung

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANN. PHARM. FR. (1989), 46(4), 223-32 *
CHEMICAL ABSTRACTS, vol. 85, no. 3, 19 July 1976, Columbus, Ohio, US; abstract no. 21433p, NODA, KANJI ET AL: "Quinazoline compounds" page 701; XP002135867 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MONTGINOUL, C. ET AL: "Analgesic, anticonvulsant and anti-inflammatory activities of 1H,3H-quinazoline-2,4-diones", XP002135868, retrieved from STN Database accession no. 110:165551h *
HARDTMANN, GOETZ E. ET AL: "Chemistry of 2H-3,1-benzoxazine-2,4(1H)-dione (isatoic anhydrides). 1. Synthesis of N-substituted 2H-3,1-benzoxazine-2,4(1H)-diones", JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 12, no. 3, 1975, HETEROCORPORATION. PROVO., US, pages 565 - 572, XP002135866, ISSN: 0022-152X *
PASTOR, G. ET AL: "Synthesis of new 1H,3H-quinazoline-2,4-diones", BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE., vol. 5-6, no. 2, 1975, SOCIETE FRANCAISE DE CHIMIE. PARIS., FR, pages 1331 - 1338, XP002135865, ISSN: 0037-8968 *

Also Published As

Publication number Publication date
CA2350208A1 (en) 2000-05-18
EE200100258A (et) 2002-12-16
TR200101307T2 (tr) 2002-05-21
KR20010075689A (ko) 2001-08-09
KR100855396B1 (ko) 2008-08-29
SK6072001A3 (en) 2002-01-07
BG65371B1 (bg) 2008-04-30
BR9915553A (pt) 2001-08-14
CN1151133C (zh) 2004-05-26
KR100777476B1 (ko) 2007-11-16
UA71587C2 (uk) 2004-12-15
AU771180B2 (en) 2004-03-18
NO320647B1 (no) 2006-01-09
NO20012245L (no) 2001-07-10
KR20070087027A (ko) 2007-08-27
YU31801A (sh) 2003-12-31
BG105588A (en) 2002-04-30
EA004701B1 (ru) 2004-06-24
CZ20011631A3 (cs) 2001-10-17
NO20012245D0 (no) 2001-05-07
WO2000027819A2 (de) 2000-05-18
PL348349A1 (en) 2002-05-20
HK1041882A1 (en) 2002-07-26
HRP20010402A2 (en) 2003-10-31
US7122547B1 (en) 2006-10-17
HUP0104425A2 (hu) 2002-03-28
JP2002529452A (ja) 2002-09-10
AU1045400A (en) 2000-05-29
EA200100524A1 (ru) 2002-02-28
EP1129074A2 (de) 2001-09-05
NZ511413A (en) 2004-01-30
CN1325384A (zh) 2001-12-05
HUP0104425A3 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
WO2000027819A3 (de) Anthranilsäureamide und deren verwendung als arzneimittel
WO2001085715A3 (de) Aza- und polyazanthranylamide und deren verwendung als arzneimittel
YU82702A (sh) Ortosupstituisani amidi antranilne kiseline i njihova primena kao sredstva za lečenje
NZ521681A (en) Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
WO2001045679A3 (de) Verwendung von chemotherapeutika zur topischen behandlung
MX9604378A (es) Amidas de acido quinolin-2-carboxilico sustituidas, su preparacion y su empleo como medicamentos, asi como productos intermedios.
WO2003032994A3 (de) 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
TW352384B (en) Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
EP1140840A4 (de) -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
WO2000035919A3 (en) Quinoline derivatives
HUP0303296A3 (en) Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours, process for their preparation and pharmaceutical compositions containing them
EP1251126A3 (de) Fluor-substituierte benzensulfonyl-derivate zur behandlung von entzündungen
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
WO1998041513A3 (de) Substituierte aminosalicylsäureamide mit fungizider wirkung und zwischenprodukte zu ihrer herstellung
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2001051044A3 (en) Substances for use in treating psoriasis
IL141325A0 (en) Tan-1057 derivatives
MXPA03008186A (es) Amidas de acidos carboxilicos antitromboticas, su preparacion y su uso como medicamentos.
WO2002060382A3 (en) Novel compounds and uses thereof
WO2003024996A3 (de) Antibakterielle makrozyklen
WO2002070537A3 (en) Fusidic acid derivatives
HK1050203A1 (en) Novel fusidic acid derivatives.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-318/01

Country of ref document: YU

Ref document number: 99813078.8

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 10454

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999953967

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 142618

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00422/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 511413

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: A 2001 00481

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 6072001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2350208

Country of ref document: CA

Ref document number: 2350208

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017005800

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 580999

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-1631

Country of ref document: CZ

Ref document number: 10454/00

Country of ref document: AU

Ref document number: 2001/01307

Country of ref document: TR

Ref document number: PA/a/2001/004692

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: P20010402A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2001/04673

Country of ref document: ZA

Ref document number: 200104673

Country of ref document: ZA

Ref document number: 200100524

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 1999 105588

Country of ref document: BG

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020017005800

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999953967

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09831506

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2001-1631

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 10454/00

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020017005800

Country of ref document: KR